2011
Presence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with R0 Resected Pancreatic Cancer
Matthaei H, Hong SM, Mayo SC, dal Molin M, Olino K, Venkat R, Goggins M, Herman JM, Edil BH, Wolfgang CL, Cameron JL, Schulick RD, Maitra A, Hruban RH. Presence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with R0 Resected Pancreatic Cancer. Annals Of Surgical Oncology 2011, 18: 3493-3499. PMID: 21537863, PMCID: PMC3166423, DOI: 10.1245/s10434-011-1745-9.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaPancreatic intraepithelial neoplasiaResection marginsTransection marginR0 resectionIntraepithelial neoplasiaPanIN lesionsPanIN-3High-grade PanIN lesionsImportant clinicopathologic characteristicsPancreatic resection marginPancreatic transection marginPresence of PanINOverall median survivalIntraoperative frozen sectionSignificant survival differenceSignificant clinical implicationsGrades of PanINsR1 resectionStrong prognosticatorMedian survivalAdditional resectionClinicopathologic characteristicsClinicopathologic factorsSurgical margins
2010
Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer)
Yoshimura K, Olino K, Edil BH, Schulick RD, Oka M. Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer). Surgery Today 2010, 40: 404-410. PMID: 20425541, DOI: 10.1007/s00595-009-4120-8.Peer-Reviewed Original ResearchConceptsCurrent treatment modalitiesNovel therapeutic approachesGene therapySurgical resectionTreatment arsenalTumor recurrenceCancer patientsTreatment modalitiesClinical trialsTherapeutic approachesGene therapeutic strategiesVivo modelCancerImmunotherapyTherapyFurther investigationPotential additionResectionChemotherapyPatientsRecurrenceMortalityTrialsCare